Compare ITRM & POAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ITRM | POAS |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | Ireland | Singapore |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.3M | 22.9M |
| IPO Year | 2018 | N/A |
| Metric | ITRM | POAS |
|---|---|---|
| Price | $0.17 | $1.56 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 561.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.43 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $947.65 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.14 | $0.53 |
| 52 Week High | $1.49 | $7.40 |
| Indicator | ITRM | POAS |
|---|---|---|
| Relative Strength Index (RSI) | 36.94 | 41.66 |
| Support Level | $0.14 | $0.53 |
| Resistance Level | $0.39 | $2.27 |
| Average True Range (ATR) | 0.02 | 0.30 |
| MACD | 0.00 | 0.07 |
| Stochastic Oscillator | 21.36 | 39.32 |
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
Phaos Technology Holdings Cayman Ltd is an investment holding company incorporated in the Cayman Islands. Through its subsidiaries, the Company engages in the research, development, manufacturing, and commercialization of advanced optical technologies and products. Leveraging its patented microsphere technology, Phaos enhances the magnification of traditional optical microscopes, enabling visualization beyond the 200nm optical limit at a commercially viable working distance. The Company offers advanced microscopy equipment and parts, along with AI-powered software solutions that complement its hardware to deliver fully integrated microscopy systems. Its technologies serve diverse sectors, including manufacturing, biomedical, and research.